抗生素耐藥性與抗生素技術之全球市場 是由出版商BCC Research在2009年11月所出版的。
這份英文市場調查報告書包含136 pages 價格從美金4850起跳。
本研究報告詳細分析全球抗生素耐藥性與抗生素技術市場。以2008市場資料為基礎，將2009至2014年之成長比例、各種商品概要、政府規範等議題，分析整理如下。
第1章 導論
第2章 摘要
第3章 概論
- 微生物感染
- 抗生素與抗生素耐藥性問題
- 細菌：分類、鑑定、耐藥性
- 革蘭氏陽性菌
- 革蘭氏陰性菌
- 微生物
- 螺旋體
- 病原分布
- 感染對策
- 消化器官細菌與其他微生物
- 大規模使用阿伏霉素之規範 等
第4章 規制動向
- 細菌耐性の政策
- 農業用抗生物質：規制動向
- 人間の治療に用いられる抗生物質
- 大規模なAVOPARCIN使用に対する規制措置 他
第5章 產品
第6章 技術動向與專利分析
- 新型抗生素之研發動向
- 細菌感染
- 噬菌體治療
- 專利分析
第7章 業界結構
- 抗生素領域的復活
- 備受矚目之生技產業
- 大藥廠關心的領域
- 針對抗生素市場之企業
- 抗生素市場與預測
- 抗生素市場之主要企業
- 企業資料
Abstract
THIS REPORT WILL:
- Provide an in-depth review of the global market for antibiotics resistance
and antibiotics technologies
- Offer an analysis of antibiotics resistance from an historical vantage
point
- Measure the current global market for antibiotics resistance and
antibiotics technologies and provide market data for 2008, estimates for 2009,
and compound annual growth rates (CAGRs) through 2014
- Describe various products by classes, including penicillins and
cephalsporins
- Profile key players in the antibiotics market
- Looks at government regulations adopted in various markets to combat
antibiotics resistance.
SCOPE OF REPORT
The scope of this report includes current antibiotic markets as well as the
emerging antibiotic market, with an exclusive focus on antibiotic resistance.
It technically encompasses antibacterials that include antibiotics, bacterial
vaccines, and other emerging antibacterials that are not necessarily
classified as antibiotics. Prevention of bacterial infections using bacterial
vaccines is within the scope of the study. Antiviral and antifungal products
are excluded from the market definition, and vaccines targeting viral diseases
are outside the scope of this study. In short, this report contains: Overview
of antibiotic market Classification of bacteria Classification of antibiotics
Mechanisms of resistance by bacteria Resistance trends and geographic analysis
Antibiotics targeted to counter the resistance mechanisms Emerging regulatory
trends Technology trends in combating resistance Patent analysis Current
antibiotic market and future growth trends Emerging new approaches and product
candidates in antibiotic resistance Analysis of leading companies and their
strategies Sales projections through 2014 for antibiotic resistance markets
The base year of this study is 2009. Market figures are based on the revenues
at the supplier levels, which are projected in 2009 constant dollars (i.e.,
inflation is not computed into the projection figures). The revenue figures
are derived from the revenues of the key players in a particular year.
Revenues of generic products are outside the scope of this study. Projections
for the antibiotic resistance market are based on the assumption that the new
and emerging products combat the antibiotic resistance issue in one way or
another. Hence, forecasts are for the antibiotic resistance markets and are
based mainly on the projections of the marketers.
INFORMATION SOURCES AND METHODOLOGY
Both primary and secondary research methods were used in this market research
study. The information and analysis presented in this report are based on an
extensive survey of the antibacterial sector as well as a detailed examination
of published literature and reports obtained from regulatory authorities,
research institutions, trade associations, and national and international
healthcare organizations. Key information from the literature was used to
obtain expert opinion on commercial potential and market sizes from industry
professionals. Data to prepare this study were derived from regulatory
agencies, annual reports of companies, scientific associations, public
healthcare authority websites, and industry related databases. In addition,
discussion with researchers and sales personnel of drug companies, academic
researchers, and government agency spokespersons have been conducted to gain
insight into the emerging market trends.
ANANLYST' S CREDENTIALS
Syamala Ariyanchira is a bench scientist who transferred to industry analysis.
She combines her technical background with business sector issues and is
involved in various activities, including technology assessment, strategic
planning, competitor analysis, due diligence, and market analysis. Her clients
include investment firms, government agencies, and chemical and pharmaceutical
companies. She holds a PhD from Indian Institute of Science, Bangalore, India,
and has authored three recent reports for BCC Research.
Table of Contents
Antibiotic Resistance and Antibiotic Technologies: Global Markets
Chapter- 1: INTRODUCTION -- Complimentary
- STUDY GOAL AND OBJECTIVES
- REASONS FOR DOING THE STUDY
- INTENDED AUDIENCE
- SCOPE OF REPORT
- INFORMATION SOURCES AND METHODOLOGY
- ANANLYST' S CREDENTIALS
- RELATED BCC RESEARCH REPORTS
- BCC ONLINE SERVICES
- DISCLAIMER
Chapter-2: EXECUTIVE SUMMARY
- EXECUTIVE SUMMARY
- SUMMARY TABLE CURRENT ANTIBIOTICS AND NEW PRODUCTS IN THE GLOBAL MARKET,
THROUGH 2014 ($ BILLIONS)
- SUMMARY FIGURE GLOBAL ANTIBIOTICS MARKET BY PRODUCT CLASSES, 2009 (%)
Chapter-3: OVERVIEW
- MICROBIOLOGY OF INFECTION
- ANTIBIOTICS AND THE PROBLEM OF ANTIBIOTIC RESISTANCE
- TABLE 1 ANTIBIOTIC DISCOVERY AND RESISTANCE DEVELOPMENT
- BACTERIA: CLASSIFICATION, IDENTIFICATION, AND RESISTANCE STATUS OF VARIOUS
CLASSES
- GRAM POSITIVE BACTERIA
- Bacillus Anthracis
- Clostridium
- C. Botulinum
- C. Difficle
- C. Perfringens
- C. Tetani
- Corynebacterium Diphtheriae
- Enterococci
- Erysipelothrix Rhusiopathiae
- Nocardia Asteroides
- Pneumococcus
- Staphylococcus
- Streptococcus
- GRAM-NEGATIVE BACTERIA
- Bordetella Pertussis
- Brucella
- Campylobacter
- Enterobacteriaceae
- Cedecea
- Citrobacter
- Enterobacter
- Escherichia coli
- Klebsiella
- Salmonella
- Shigella
- Haemophilus
- Neisseria
- Vibrio cholerae
- MYCOBACTERIA
- Mycobacterium Tuberculosis
- TABLE 2 U.S. TUBERCULOSIS CASES AND DEATHS, 1998 - 2007
- Mycobacterium Leprae
- Mycobacteria other than Tuberculosis (MOTT)
- SPIROCHETES
- Borrelia Burgdorferi
- Treponema Pallidum
- PATHOGEN DISEASE DISTRIBUTION
- TABLE 3 ESTIMATED DISEASE INCIDENCE BY BACTERIA IN SELECTED COUNTRIES,
2007
- COMPARISON OF NOCOSOMIAL AND COMMUNITY INFECTIONS
- Hospital-Acquired (HA)-MRSA
- Community-Associated (CA)-MRSA
- NATURAL DEFENSES PRESENT IN THE COMBAT OF INFECTION
- ANTISEPTICS
- BACTERIA AND OTHER MICROORGANISMS OF THE DIGESTIVE TRACT
- CLASSIFICATION OF ANTIBIOTICS
- BACTERICIDAL AND BACTERIOSTATIC
- CLASSIFICATION BASED ON STRUCTURE
- Penicillins
- Cephalosporins
- Fluoroquinolones
- Tetracyclines
- Macrolides
- TABLE 4 COMMONLY USED ANTIBIOTICS BY CLASS
- CLASSIFICATION BASED ON THE MODE OF ACTION OF ANTIBIOTICS
- Cell Wall Inhibitors
- Cell Membrane Inhibitors
- Nucleic Acid Inhibitors
- Protein Synthesis Inhibitors
- TABLE 5 COMMONLY USED PROTEIN SYNTHESIS INHIBITORS
- Metabolic Inhibitors
- Fatty Acid Biosynthesis (Fab) Inhibitors
- ADMINISTRATION OF ANTIBIOTICS
- DETERMINING THE POTENCY OF ANTIBIOTICS
- ANTIBIOTIC SUSCEPTIBILITY TESTING
- DRUG RESISTANCE: THE GREATEST CHALLENGE FACING THE ANTI-INFECTIVE DRUG
MARKET
- THE HISTORY OF ANTIBIOTIC RESISTANCE
- CURRENT CRISIS OF ANTIBIOTIC RESISTANCE
- THE MICROBIOLOGY OF ANTIBIOTIC RESISTANCE
- MECHANISMS OF RESISTANCE DEVELOPED BY VARIOUS BACTERIA
- Enzymatic Deactivation or Modification of Antibiotic
- ESBL-Producing Organisms
- Alteration of the Target Site of the Antibiotic
- Alteration of the Metabolic Pathways
- Reducing the Potential for Drug Accumulation
- Biofilm Formation
- TABLE 6 HUMAN INFECTIONS INVOLVING BIOFILMS
- RESISTANCE IN GRAM-POSITIVE BACTERIA
- Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Vancomycin-Intermediate S. aureus (VISA)
- Vancomycin-Resistant Enterococci (VRE)
- Multi-Drug-Resistant Clostridium difficile
- RESISTANCE IN GRAM-NEGATIVE BACTERIA
- Multi-Drug-Resistant Acinetobacter Baumannii
- Enterobacteriacae- (Resistance by ESBL and AmpC-beta Lactamase Production)
- Resistance in Pseudomonas Aeruginosa
- Tetracycline-Resistant, Penicillin-Resistant Neisseria gonorrhoeae
- ANTIBIOTIC RESISTANCE IN MYCOBACTERIUM
- TABLE 7 MECHANISMS OF RESISTANCE BY BACTERIA REPORTED AGAINST VARIOUS ANTIBIOTIC CLASSES
- COST OF ANTIBIOTIC RESISTANCE
- TABLE 8 ECONOMIC PRESSURES DUE TO ANTIBIOTIC RESISTANCE, INSTITUTIONAL AND SOCIETAL
- EFFECTS OF INCREASING ANTIBIOTIC RESISTANCE
- TABLE 9 TREATMENT OPTIONS FOR RESISTANT BACTERIA
- TABLE 9 (CONTINUED)
- ANTIBIOTIC STEWARDSHIP PROGRAMS IN HOSPITALS
- TABLE 10 ESSENTIAL COMPONENTS OF ANTIMICROBIAL STEWARDSHIP PROGRAMS
- TRENDS IN GEOGRAPHIC DISTRIBUITION OF RESISTANCE
- Europe
- U.S.
- TABLE 11 U.S. ANTIBIOTIC RESISTANCE TRENDS OF SOME CRITICAL INFECTIONS
- TABLE 11 (CONTINUED)
- Global Epidemiology Trends of Antibiotic Resistance: Rest of the World
- TABLE 12 REST OF THE WORLD EPIDEMIOLOGY TRENDS OF ANTIBIOTIC RESISTANCE
Chapter-4: REGULATORY TRENDS
- POLITICS OF BACTERIAL RESISTANCE
- AGRICULTURAL ANTIBIOTICS: REGULATORY TRENDS
- TABLE 13 U.S.-APPROVED AGRICULTURAL ANTIMICROBIALS
- TABLE 14 AGRICULTURAL ANTIBIOTICS THAT CAN CROSS-SELECT ANTIBIOTICS USED TO TREAT HUMANS
- TABLE 15 COMMON ANTIBIOTICS IN USE IN LIVESTOCK AND HUMANS
- REGULATORY ACTIONS AGAINST LARGE-SCALE USE OF AVOPARCIN
- TABLE 16 REGULATORY ACTIONS TAKEN BY GOVERNMENTS TO CONTROL AGRICULTURAL USE OF AVOPARCIN
- PREVALENCE OF FLUOROQUINOLONE RESISTANCE DUE TO AGRICULTURAL USAGE
- TABLE 17 FLUOROQUINOLONES USED IN AGRICULTURE
- TABLE 18 U.S. REGULATORY ACTIONS CONTROLLING AGRICULTURAL USE OF FLUOROQUINOLONES
- INTERNATIONAL EFFORTS TO ADDRESS MICROBIAL RESISTANCE
- ACTION ON ANTIBIOTIC RESISTANCE (REACT)
- ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS (APUA)
- EFFORTS BY THE WORLD HEALTH ORGANIZATION (WHO)
- TABLE 19 ANTIBIOTICS OF CRITICAL IMPORTANCE TO HUMAN MEDICINES CATEGORIZATION BY THE WORLD HEALTH ORGANIZATION
- REGULATORY TRENDS IN U.S.
- TABLE 20 U.S. REGULATORY BODIES AND OTHER AGENCIES INVOLVED IN MONITORING AGRICULTURAL ANTIBIOTICS
- Role of the FDA
- Impact of Regulations on Innovation
- EFFORTS BY EUROPEAN REGULATORY AGENCIES
- European Centre for Disease Prevention and Control (ECDC)
- European Food Safety Authority (EFSA)
- TABLE 21 E.U. KEY INITIATIVES TOWARD CONTAINING ANTIBIOTIC RESISTANCE
- TABLE 22 PROJECTS UNDER DG-SANCO ADDRESSING ANTIBIOTIC RESISTANCE
- TABLE 22 (CONTINUED)
- REGULATORY TRENDS IN ASIA
- Australia
- China
- India
- Japan
- South Korea
- Taiwan
- Taiwan (Continued)
Chapter-5: PRODUCTS
- PRODUCTS TARGETED AT ANTIBIOTIC RESISTANCE
- TABLE 23 KEY PRODUCTS TARGETING ANTIBIOTIC RESISTANCE
- LEVAQUIN
- ZOSYN/TAZOCIN
- AVELOX
- CUBICIN
- ANTIBACTERIAL DRUGS IN DEVELOPMENT BY CLASS OF PRODUCT
- BETA LACTAM ANTIBIOTICS
- TABLE 24 B-LACTAM ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED
- Doripenem
- Tomopenem
- PZ-601
- Faropenem
- Ceftaroline
- Ceftobiprole
- BAL-30072
- FR-264205
- TABLE 25 B-LACTAM ANTIBIOTICS, IN DEVELOPMENT OR RECENTLY MARKETED
- TABLE 25 (CONTINUED)
- FLUOROQUINOLONES
- TABLE 26 FLUOROQUINOLONE ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED
- Sitafloxacin
- Garenoxacin
- Delafloxacin
- WCK-771
- Zabofloxacin
- DC-159a
- GLYCOPEPTIDES
- TABLE 27 GLYCOPEPTIDE ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED
- Dalbavancin
- Oritavancin
- Telavancin
- Ramoplanin
- MACROLIDES
- TABLE 28 MACROLIDE ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED
- Cethromycin
- EDP-420
- Fidaxomicin
- OXAZOLIDINONES
- TABLE 29 OXAZOLIDINONE ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED
- Radezolid
- Torezolid
- OTHER CLASSES OF ANTIBIOTICS IN PIPELINE
- TABLE 30 EMERGING CLASSES OF ANTIBIOTICS
- TABLE 31 OTHER CLASSES OF ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED
- TABLE 31 (CONTINUED)
- TABLE 31 (CONTINUED)
- Iclaprim
- PTK 0796
- AFN-1252
- Friulimicin
- Rifalazil
- Pagibaximab
- Nemonoxacin
- Platensimycin
- NXL-103
- BC-3205 and BC-3781
- PMX-30063
- KBPA-101
- KB-001
- ACHN-490
- CB-182804
- VACCINES
- TABLE 32 VACCINES AGAINST BACTERIAL INFECTIONS IN DEVELOPMENT OR NEWLY INTRODUCED
- Menveo
- Prevnar 13vPnC
- Synflorix
- V710
- IC43
Chapter-6: TECHNOLOGY TRENDS AND PATENT ANALYSIS
- DECLINING TRENDS OF INNOVATION IN THE DEVELOPMENT OF NEW ANTIBIOTICS
- TABLE 33 U.S. FDA-APPROVED SYSTEMIC ANTIBACTERIAL NMES, 1983 - 2008
- BROAD-SPECTRUM VERSUS NARROW-SPECTRUM ANTIBIOTICS
- TABLE 34 SYSTEMIC ANTIBIOTICS TARGETING MRSA IN CLINICAL DEVELOPMENT
- TABLE 34 (CONTINUED)
- TABLE 35 ANTIBACTERIALS AGAINST MDR-GRAM-NEGATIVE BACTERIA IN CLINICAL DEVELOPMENT
- TABLE 35 (CONTINUED)
- NEW FOCUS ON GRAM-NEGATIVE PATHOGENS
- ANALOGUES OF EXISTING ANTIBIOTICS VS NOVEL MOLECULES/ TARGETS
- TABLE 36 ANALOGUES OF EXISTING DRUGS AND NEW MOLECULES
- CATIONIC PEPTIDES AS NEW GENERATION ANTIBACTERIALS FOR THERAPEUTIC USE
- TABLE 37 COMPARISON OF CATIONIC PEPTIDE ANTIBIOTICS AND CONVENTIONAL ANTIBIOTICS
- TABLE 38 CATIONIC ANTIBACTERIAL PEPTIDES FOR SYSTEMIC ADMINISTRATION, UNDER DEVELOPMENT
- BACTERIAL INTERFERENCE: A NEW APPROACH FOR THE TREATMENT OF BACTERIAL
INFECTIONS
- BACTERIOPHAGE THERAPY
- PATENT ANALYSIS
- TABLE 39 U.S. PTO-GRANTED PATENTS BY ANTIBIOTIC STRUCTURAL CLASSES, 1976 - SEPTEMBER 8, 2009
- TABLE 40 TRENDS IN PATENTING OF BIG PHARMA COMPANIES RELATED TO ANTIBIOTICS*
- TABLE 41 PATENTS IN ANTIBIOTICS BY NEW AND EMERGING COMPANIES, 1976 - SEPTEMBER 8, 2009
- TABLE 41 (CONTINUED)
Chapter-7: INDUSTRY STRUCTURE
- REVIVAL OF ANTIBIOTIC SECTOR
- RISING PRESENCE OF BIOTECH COMPANIES
- TABLE 42 SELECTED BIOTECH ANTIBACTERIALS IN DEVELOPMENT
- TABLE 42 (CONTINUED)
- REVIVAL OF THE SECTOR WITH RENEWED INTEREST OF BIG PHARMA
- TABLE 43 RECENT INVESTMENTS OR PARTNERSHIPS BY BIG PHARMA COMPANIES TARGETING THE ANTIBIOTICS SECTOR
- TABLE 43 (CONTINUED)
- GLOBAL MARKET FOR ANTIBIOTICS AND FORECASTS
- TABLE 44 GLOBAL GROWTH TRENDS FOR CARBAPENEM ANTIBIOTICS, THROUGH 2014 ($ MILLIONS)
- FIGURE 1 GLOBAL GROWTH TRENDS FOR CARBAPENEM ANTIBIOTICS, 2008-2014 ($ MILLIONS)
- TABLE 45 GLOBAL GROWTH TRENDS FOR CEPHALOSPORIN ANTIBIOTICS, THROUGH 2014 ($ MILLIONS)
- FIGURE 2 GLOBAL GROWTH TRENDS FOR CEPHALOSPORIN ANTIBIOTICS, 2008-2014 ($ MILLIONS)
- TABLE 46 GLOBAL GROWTH TRENDS OF MACROLID ANTIBIOTICS, THROUGH 2014 ($ MILLIONS)
- FIGURE 3 GLOBAL GROWTH TRENDS OF MACROLID ANTIBIOTICS, 2008-2014 ($ MILLIONS)
- TABLE 47 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS, THROUGH 2014 ($ MILLIONS)
- FIGURE 4 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS, 2008-2014 ($ MILLIONS)
- TABLE 48 GLOBAL MARKET FOR FLUOROQUINOLONES, THROUGH 2014 ($ MILLIONS)
- FIGURE 5 GLOBAL MARKET FOR FLUOROQUINOLONES, 2008-2014 ($ MILLIONS)
- TABLE 49 GLOBAL MARKET FOR BACTERIAL VACCINES, THROUGH 2014 ($ MILLIONS)
- FIGURE 6 GLOBAL MARKET FOR BACTERIAL VACCINES, 2008-2014 ($ MILLIONS)
- TABLE 50 GLOBAL ANTIBIOTIC MARKETS, THROUGH 2014 ($ MILLIONS)
- FIGURE 7 GLOBAL ANTIBIOTIC MARKETS, 2008-2014 ($ MILLIONS)
- LEADING COMPANIES IN THE ANTIBIOTICS MARKET
- TABLE 51 TOP PLAYERS AND KEY PRODUCTS IN THE ANTIBIOTICS MARKET
- TABLE 51 (CONTINUED)
- COMPANY PROFILES
- ACHAOGEN, INC.
- ADVANCED LIFE SCIENCES
- AFFINIUM PHARMACEUTICALS
- ARPIDA, LTD.
- BASILEA PHARMACEUTICA LTD.
- BAYER SCHERING PLOUGH AG
- BIOSYNEXUS INC.
- CUBIST PHARMACEUTICALS, INC.
- ENANTA PHARMACEUTICALS
- GLAXO SMITHKLINE PLC
- TABLE 52 GSK' S PIPELINE ANTIBIOTICS AND BACTERIAL VACCINE PRODUCTS
- TABLE 52 (CONTINUED)
- INTERCELL AG
- TABLE 53 INTERCELL AG' S ANTI-BACTERIAL PIPELINE PRODUCTS
- KALOBIOS PHARMACEUTICALS, INC.
- KENTA BIOTECH LTD.
- JOHNSON &JOHNSON
- MERCK & CO. INC.
- MPEX PHARMACEUTICALS
- NABRIVA THERAPEUTICS AG
- NOVABAY PHARMACEUTICALS, INC.
- NOVARTIS INTERNATIONAL AG
- TABLE 54 NOVARTIS' BACTERIAL VACCINE PIPELINE
- NOVEXEL
- OPTIMER PHARMACEUTICALS, INC.
- OSCIENT PHARMACEUTICALS CORPORATION
- PARATEK PHARMACEUTICALS, INC.
- PFIZER, INC.
- POLYMEDIX, INC.
- REPLIDYNE, INC.
- RIB-X PHARMACEUTICALS, INC.
- SANOFI-AVENTIS
- TABLE 55 SANOFI-AVENTIS' S BACTERIAL VACCINE CANDIDATES
- TAIGEN BIOTECHNOLOGY CO., LTD.
- THERAVANCE, INC.
- TRIUS THERAPEUTICS
- WYETH PHARMACEUTICALS
- TABLE 56 WYETH' S ANTIBACTERIAL PIPELINE
- APPENDIX
- TABLE 57 ABBREVIATIONS
- TABLE 57 (CONTINUED)
- TABLE 57 (CONTINUED)
|
